positive results

Genocea Reports Third Quarter 2015 Financial Results
www.businesswire.com

On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Today's Watch List: General Motors Company (NYSE:GM), Genocea Biosciences, Inc …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save
Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …
www.senecaglobe.com

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
Genocea (GNCA) Stock | Shares Trade Higher on Phase 2 Results
www.warriortradingnews.com

Wednesday they announced positive results from an interim study of data collected over a six month period dosing from its ongoing Phase 2 dose optimization trial evaluating their pipeline drug, GEN-003 for the treatment of genital herpes. When …

2
Like
Save
Premarket Biotech Digest: Evoke Pharma Rallies, Avelumab Fast Tracked, Vertex …
seekingalpha.com

… Phase II Trial of GEN-003 – Genocea Biosciences (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its Phase II dose optimization trial of GEN-003 for the treatment of genital herpes.

2
Like
Save